Hisun Pharmaceutical and Pfizer launch a JV targeting the Chinese biosimilars market

March 06, 2012 | Analyst Insight

Hisun Pharmaceutical and Pfizer have signed JV framework contract with tentative name Hisun-Pfizer Pharmaceutical with registered capital of $250 million, but a total invested amount of $295 million. Hisun will hold 51% of the...

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978

© 2004-2021 Lux Research, Inc. All Lux Research content is intended only for consumption by Lux Research clients; redistribution is prohibited and copyright is strictly enforced. All material is based on information obtained from sources believed to be reliable but no independent verification has been made, nor is its accuracy or completeness guaranteed. All material is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments.